Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

46.79
Delayed Data
As of Jul 29
 +0.07 / +0.15%
Today’s Change
37.59
Today|||52-Week Range
58.05
-13.46%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Generic
MARKET CAP
$23.9B

Company Description

Mylan N.V., is a pharmaceutical company which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceutical products. It operates through two segments: Generic and Specialty. The Generic pharmaceutical business is conducted primarily in the U.S. and Canada; Europe; and India, Australia, Japan, New Zealand and Brazil as well as its export activity into emerging markets. The Specialty pharmaceutical business is conducted by Mylan Specialty L.P.. The company was founded on July 7, 2014 and is headquartered in Hatfield, United Kingdom.

Contact Information

Mylan NV
Building 4
Hatfield Hertfordshire EN6 1AG
P:441707853000
Investor Relations:
(724) 514-1831

Employees

Shareholders

Other institutional35.32%
Mutual fund holders35.07%
Individual stakeholders14.47%

Top Executives

Heather M. BreschChief Executive Officer & Executive Director
Rajiv MalikPresident & Executive Director
Kenneth Scott ParksChief Financial Officer
Anthony MauroChief Commercial Officer
Kris KingVice President-Global Investor Relations